Hydroxyurea in the treatment of HIV-1 infection: Toxicity and side effects

Journal of Biological Regulators and Homeostatic Agents

Volumn 13, Issue 3, 1999, Pages 181-185

  Maserati, R ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Adverse events; AIDS; HIV 1 infection; Hydroxyurea; Toxicity

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; NELFINAVIR; PLACEBO; RITONAVIR; STAVUDINE; VIRUS DNA; ZIDOVUDINE;

ALOPECIA; ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DISEASE SEVERITY; DNA SYNTHESIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; IMMUNE DEFICIENCY; LONG TERM CARE; NAUSEA; NEUROPATHY; NEUTROPENIA; ONCOLOGY; PERIPHERAL CIRCULATION; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0033303144     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hydroxyurea. A new type of potential antitumor agent
2. Uber die Beziehungen von schwersten Blutgiften zu Abbauprodukten des Eiweisses: Ein Beitrag zum Entstehungmechanismus der pernizosen Anemie
3. An overview of the clinical experience with hydroxyurea
4. Hydroxyurea (NSC 32065): Results of a phase I study
5. A phase I study of hydroxyurea
6. Skin changes secondary to hydroxyurea
7. Hydroxyurea-induced hepatitis
8. Renal abnormalities induced by hydroxyurea
9. Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit HIV-1 type replication
10. Anti-HIV-1 activity of the combination of didanosine and hydroxyurea in HIV-1 infected individuals
11. 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV-1 infection
12. Treatment of Human Immunodeficiency Virus infection with hydroxyurea: Virologic and clinical evaluation
13. Hydroxyurea treatment in HIV-1-infected patients
14. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV-1) disease receiving chronic didanosine therapy: Canadian HIV-1 trials network protocol 080
15. Combination of a drug treatment targeting the cell with a drug targeting the virus controls Human Immunodeficiency Virus type 1 resistance
16. Hydroxyurea toxicity - when combined with didanosine (didanosine) - in HIV-1 seropositive asymptomatic individuals
17. A placebo-controlled trial of didanosine polus stavudine, with and without hydroxyurea, for HIV-1 infection
18. Hydroxyurea in combination regimens for the treatment of antiretroviral naive, HIV-1-infected adults
19. D4T/didanosine plus hydroxyurea: An alternative to PI containing triple regimen in ART-naive HIV-1+ patients?
20. Rapid viral load reduction with a regimen of nelfinavir, stavudine, didanosine and hydroxyurea
21. Hydroxyurea (HU) plus didanosine as salvage therapy in HIV-1
22. Treatment with d4T + didanosine + nelfinavir + hydroxyurea for early or recent primary HIV-1 infection
23. A pilot randomized comparative study of stavudine (d4T) + didanosine (didanosine) + nevirapine (NVP) with or without hydroxyurea (HU) in primary HIV-1 infection (PHI)
24. Surrogate Marker responses to multidrug combinations comprising hydroxyurea, efavirenz, double protease inhibitors and nucleoside analogues in protease inhibitor failures
25. Phase I/II dosing study of once-daily hydroxyurea (HU) alone vs. didanosine (didanosine) alone vs. didanosine + HU
26. Tailoring drug treatments with the use of hydroxyurea
27. Immunologic and virologic effects of hydroxyurea in a cohort of heavily pretreated patients